Navigation Links
Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
Date:1/9/2014

DUBLIN, January 9, 2014 /PRNewswire/ --

Dublin - Research and Markets (http://www.researchandmarkets.com/research/pkv9nd/liver_diseases) has announced the addition of the "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with their compound annual growth rate.

This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players. The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product portfolio and recent developments is also provided in the report.

We have used secondary research for deriving our market numbers for each segment of the research report and further validated our analysis with C-level executives of major companies operating in liver diseases therapeutics market through the means of primary research to finally come up with our results. This research is specially designed to estimate and analyze the performance of liver diseases therapeutics in a global scenario. This research provides in-depth analysis of liver diseases therapeutics market sales, trend analysis by segments.

Key Topics Covered:

1 Preface
1.1 Report Description
1.2 Research Methodology

2 Executive Summary

3 Market Overview
3.1 Introduction
3.2 Market Size
3.3 Comparative Analysis Of Global Liver Diseases Therapeutics Market, By Drug Class, 2011 & 2018
3.4 Liver Diseases Therapeutics Market Dynamics
3.5 Porter's Five Forces Analysis For Liver Diseases Therapeutics Market

4 Liver Diseases Classification And Therapy Options
4.1 Alcohol Induced Liver Disease
4.2 Autoimmune Liver Disorder
4.3 Hepatocellular Carcinoma
4.4 Non-Alcoholic Fatty Liver Disease
4.5 Viral/Hepatitis Liver Disorder

5 Liver Diseases Therapeutics Market, By Drug Class
5.1 Immunosuppressants
5.2 Chemotherapy Drugs
5.3 Targeted Therapy Drugs
5.4 Vaccines
5.5 Anti-Viral Drugs
5.6 Immunoglobulins
5.7 Corticosteriods

6 Competitive Landscape

7 Recommendations
7.1 Market Strategy For Success
7.2 Barriers To Be Considered

8 Company Profiles



Companies Mentioned:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Glaxosmithkline Plc
  • F. Hoffmann-La Roche Ltdmerck & Co. Inc
  • Novartis Ag
  • Sanofi S.A
  • Pfizer Inc.
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals
  • Watson Pharmaceuticals, Inc.


For more information visit http://www.researchandmarkets.com/research/pkv9nd/liver_diseases

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
2. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
3. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
6. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
7. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
8. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
9. Direct Relief Delivers Hurricane Packs As FEMA Urges Preparedness
10. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
11. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small ... the National Institutes of Health (NIH) to ... University.  The grant will seek to ... head device, which utilizes electromagnetic waves to treat Alzheimer,s ... this novel technology to possibly treat other neurologic disorders ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):